Robert W. Baird Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price
Robert W. Baird has raised its price target for Haemonetics (NYSE:HAE) to $119 from $96, maintaining an "outperform" rating, which suggests a potential upside of 9.74%. This positive forecast aligns with a broader "Moderate Buy" consensus among analysts, with Haemonetics also reporting strong quarterly earnings that surpassed expectations. Institutional ownership in the medical instruments supplier is significant, with 99.67% of shares held by such investors.
26,280 Shares in Haemonetics Corporation $HAE Acquired by Nierenberg Investment Management Company LLC
Nierenberg Investment Management Company LLC has acquired 26,280 shares of Haemonetics Corporation (NYSE:HAE) valued at approximately $1.97 billion, making it their 15th largest holding. This acquisition comes amid positive investor sentiment for Haemonetics, driven by a new supply agreement with CSL Plasma, strong quarterly results with raised revenue-growth forecasts, and recent analyst upgrades. The company's stock opened at $108.39, near its 12-month high, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $95.00.
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE
Aurora Investment Counsel recently acquired a new position in Haemonetics Corporation (NYSE:HAE), purchasing 25,501 shares valued at approximately $1.9 million. This investment comes as Haemonetics has exceeded quarterly expectations, with management raising its full-year revenue-growth outlook, and analysts maintaining a "Moderate Buy" consensus rating for the stock. The company also recently signed a new supply agreement with CSL Plasma, further bolstering positive sentiment.
HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $118 FROM $95
Barrington Research has increased its target price for Haemonetics Corp (HAE.N) to $118 from $95. This brief report, sourced from Reuters, indicates an updated valuation for the company's stock. The article explicitly states that its content reflects the author's opinion and is not investment advice.
Haemonetics stock hits 52-week high at 106.64 USD By Investing.com
Haemonetics Corp (NYSE:HAE) reached a new 52-week high of $106.64, demonstrating strong performance with a 92.73% one-year return. This surge follows better-than-expected fiscal first-quarter results and a new supply agreement with CSL Plasma Inc. Analysts have also revised earnings upwards, indicating continued positive momentum for the company.
Haemonetics Shares Hit New 52-Week High: What's Happening?
Haemonetics Corp (NYSE: HAE) shares surged after the company announced a commercial supply agreement with CSL Plasma Inc. This agreement allows CSL Plasma to adopt Haemonetics’ NexSys PCS devices with Persona PLUS technology across its U.S. network, causing HAE stock to hit a new 52-week high. Following the news, BTIG analyst Marie Thibault reiterated a Buy rating and increased the price target for Haemonetics shares from $96 to $110.
Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating
Barrington has increased its price target for Haemonetics (HAE) to $118 from $95, while maintaining an Outperform rating on the stock. This adjustment follows several recent updates for Haemonetics, including a supply agreement with CSL Plasma and a raised fiscal 2027 outlook after strong Q1 2027 earnings.
Haemonetics Stock Jumped 16% on a CSL Plasma Deal Yesterday. Here’s What Investors Need to Know.
Haemonetics (HAE) stock surged 16% after announcing a non-exclusive supply agreement with CSL Plasma for its NexSys PCS devices and related disposables, a key "razor-and-blade" model expansion. This deal, while lacking minimum purchase commitments, has driven the stock above its consensus analyst price target for the first time in over a year, prompting some analysts to raise their objectives. However, TIKR's valuation model suggests the stock may be overvalued, pricing it at $93 compared to the current $105, arguing the market may have overpaid for the optionality of the deal before concrete financial impacts are announced.
Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution?
Haemonetics (HAE) recently reported Q1 results with rising sales but eased net income, alongside filing a $391.25 million shelf registration for ESOP-related shares. This move highlights the company's efforts to balance near-term performance with future funding needs. The article explores how these developments impact Haemonetics' investment narrative, risk profile, and the potential for shareholder dilution, given its existing high valuation and analyst forecasts for growth.
Form 8K Haemonetics Corp For: 18 August By Investing.com
This article from Investing.com is a simple notification about an 8K filing by Haemonetics Corp on August 18. It provides no further details about the content of the filing but lists the company's stock symbol (HAE) and its current performance. The article is largely composed of navigational elements and market data from Investing.com.
Haemonetics Stock Climbs As Analysts Hike Price Targets
Haemonetics Corporation's stock (HAE) has surged by 15.77% after the company reported strong fiscal Q1 earnings, beating revenue and EPS estimates, and raised its FY27 guidance. Several analysts, including Bank of America and Raymond James, have subsequently increased their price targets for HAE, citing best-in-class performance and continued growth in its core franchises. The stock's momentum is driven by its strong fundamentals, high gross margins, and a positive outlook from Wall Street.
Haemonetics Corporation Stock 12‑Month Price Target Raised to $101.8, Implies 13% Upside
Haemonetics Corporation (HAE) has seen its average 12-month price target increased to $101.8 from $99.8 by analysts, suggesting a 13% potential upside from its recent closing price. The consensus rating for the stock remains a "Buy" among 12 covering analysts. Forecasts for the stock range from $86 to $120 per share.
Haemonetics rises after supply deal with CSL
Haemonetics (HAE) shares rose approximately 7% in premarket trading after the company announced a new supply agreement with Australian biopharma firm CSL Limited (CSLLY, CMXHF). The MedTech company, based in Boston, Massachusetts, disclosed the deal in a regulatory filing.
Haemonetics Surges 15.3% After BTIG Maintains Buy
Haemonetics Corporation saw its stock surge 15.3% to $104.05 after BTIG upgraded the medical device maker to a Buy rating and increased its price target from $96 to $110. This upgrade signals increased confidence in the company's market position and growth prospects within the medical devices sector, leading to a significant increase in trading volume and a market capitalization of $4.7 billion. Investors are now watching to see if other analysts will follow BTIG's lead and if the stock can sustain these gains.
Haemonetics announces non-exclusive supply agreement with CSL Plasma
Haemonetics Corporation has entered into a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL Plasma to use Haemonetics’ NexSys PCS devices with Persona PLUS technology. While the agreement has no minimum purchase commitments and its financial impact is still being evaluated, Haemonetics recently reported strong fiscal first-quarter results that exceeded analyst expectations, leading BTIG to raise its price target for the company.
Haemonetics signs non-exclusive U.S. supply deal with CSL Plasma for NexSys PCS devices
Haemonetics has entered a non-exclusive U.S. supply agreement with CSL Plasma to provide NexSys PCS devices with Persona PLUS technology and related disposables. While CSL Plasma may transition some U.S. plasma centers to these devices, the scope and timing are currently undetermined, and Haemonetics is not revising its fiscal 2027 guidance at this time. The company will provide an update on the anticipated impact during its Q2 earnings call in November 2026.
Rice Hall James & Associates LLC Makes New Investment in Haemonetics Corporation $HAE
Rice Hall James & Associates LLC recently invested $3.83 million in Haemonetics Corporation (NYSE:HAE) by purchasing 51,038 shares in the second quarter, contributing to the 99.67% institutional ownership of the stock. Haemonetics exceeded Q2 earnings expectations with adjusted EPS of $1.14 and revenue of $339.38 million. Analysts generally have a "Moderate Buy" rating for HAE, with an average price target of $90.89.
Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance
Haemonetics (HAE) stock has shown strong returns, but its valuation presents a mixed picture. A Discounted Cash Flow (DCF) model suggests it's undervalued by almost 49% based on expected cash flow growth, while its P/E ratio indicates it's overvalued compared to industry averages and a tailored fair P/E. The company's future performance hinges on its ability to deliver on revenue and margin targets without execution issues.
John Rogers's Top Q2 2026 Move: Haemonetics Corp at a 1.54% Portfolio Impact
John Rogers, founder of Ariel Investment, LLC, submitted his Q2 2026 13F filing, revealing strategic portfolio adjustments. His top new buy was Haemonetics Corp (NYSE:HAE), making a 1.54% portfolio impact, alongside significant increases in RLI Corp (NYSE:RLI) and Masco Corp (NYSE:MAS). Rogers also completely exited positions in Stanley Black & Decker Inc (NYSE:SWK) and Microsoft Corp (NASDAQ:MSFT) and reduced stakes in Sphere Entertainment Co (NYSE:SPHR) and Algonquin Power & Utilities Corp (NYSE:AQN).
Assenagon Asset Management S.A. Sells 142,292 Shares of Haemonetics Corporation $HAE
Assenagon Asset Management S.A. significantly reduced its stake in Haemonetics Corporation (NYSE:HAE) by selling 142,292 shares, an 80.2% reduction, leaving them with 35,109 shares valued at $2.6 million. Despite this, institutional investors collectively own 99.67% of HAE, and analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $90.89. Haemonetics also exceeded quarterly earnings and revenue expectations, demonstrating strong financial performance.
BofA Securities Adjusts Price Target on Haemonetics to $100 From $93
BofA Securities has increased its price target for Haemonetics (HAE) to $100, up from the previous $93. This adjustment reflects a positive outlook from the firm on the medical technology company. Haemonetics specializes in solutions for critical medical needs, including hospital technologies, plasma collection, and blood management.
Haemonetics (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) reported a strong Q1 2027 with broad-based growth across all core platforms, leading to raised full-year revenue guidance. The Plasma business showed significant momentum driven by share gains, strong collection trends, and the accelerated rollout of Persona PLUS. The Interventional Technologies segment also returned to growth, primarily due to Vascular Closure device performance and market stabilization.
Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Analysts
Haemonetics Corporation (NYSE:HAE) has received a consensus "Moderate Buy" rating from eleven research firms, with an average 12-month price target of $90.89. The company recently surpassed quarterly expectations, reporting $1.14 EPS and $339.38 million in revenue, leading several analysts to raise their price targets while maintaining or upgrading ratings. Institutional investors hold 99.67% of the stock.
Haemonetics Corp (HAE) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 77/100
Haemonetics Corp (HAE) shares increased by 4.7% to $91.34, approaching its 52-week high, with significant short-term and long-term momentum. Despite this rise, GuruFocus's GF Value™ indicates the stock is overvalued by 7.6% compared to its estimate of $84.90, suggesting no margin of safety for investors. HAE boasts a GF Score™ of 77/100, reflecting above-average quality driven by strong profitability, but its valuation metrics and lack of recent insider activity point to potential overvaluation.
AQR Capital discloses 4.99% Haemonetics Corp (HAE) position in Schedule 13G/A
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have disclosed a beneficial ownership of 4.99% in Haemonetics Corp (HAE) common stock. This position, totaling 2,266,489 shares, was reported in a Schedule 13G/A filing as of June 30, 2026. The entities share voting power over 2,149,735 shares and shared dispositive power over all 2,266,489 shares.
Quantinno Capital Management LP Has $1.73 Million Stock Holdings in Haemonetics Corporation $HAE
Quantinno Capital Management LP significantly increased its stake in Haemonetics Corporation (NYSE:HAE) by 438% in the first quarter, bringing its total holdings to 30,708 shares valued at $1.73 million. Haemonetics reported strong quarterly results, beating analyst expectations with $339.38 million in revenue and $1.14 EPS, contributing to a "Moderate Buy" consensus rating from analysts. Institutional investors hold a substantial 99.67% of the company's stock, and several analysts have recently raised their price targets for HAE.
Does Strong Q1 Results And VASCADE Data Shift The Bull Case For Haemonetics (HAE)?
Haemonetics Corporation reported stronger-than-expected Q1 results with increased sales and diluted EPS, along with positive new Emory University study data reinforcing the safety and efficiency of its VASCADE MVP XL venous vascular closure system. These developments, particularly the VASCADE data, are seen as significant for strengthening the company's interventional technologies growth engine and could potentially reshape existing pessimistic investment scenarios, despite ongoing concerns about U.S. market concentration and competition. The article suggests that VASCADE's performance is crucial for Haemonetics' investment narrative and future growth.
Haemonetics stock hits 52-week high at 88.73 USD
Haemonetics Corp's stock reached a new 52-week high of $88.73, marking a significant 67.34% increase over the past year and reflecting strong investor confidence. The medical technology company's market capitalization stands at $3.97 billion, with its P/E ratio of 42 suggesting it may be undervalued according to InvestingPro. This achievement follows strong fiscal first-quarter results that surpassed Wall Street expectations, leading BTIG to raise its price target to $96.
Renaissance Technologies LLC Takes $2.44 Million Position in Haemonetics Corporation $HAE
Renaissance Technologies LLC has acquired a new position in Haemonetics Corporation, purchasing 43,200 shares valued at approximately $2.44 million. Haemonetics maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $90.89, following strong quarterly earnings that surpassed expectations. Institutional investors and hedge funds now collectively own 99.67% of the medical instruments supplier.
Haemonetics Corporation (HAE) Stock forecasts
Argus has raised its target price for Haemonetics Corporation (HAE) stock to $90.00. The company, currently trading at $86.61, focuses on improving patient care and reducing healthcare costs through its medical products and solutions for blood and plasma collection, surgical suites, and hospital transfusion services. This report provides a summary of the analysis with an option to download the full report.
Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen has upgraded Haemonetics (NYSE:HAE) to a "strong-buy" rating, reflecting positive analyst sentiment and strong financial performance. The company exceeded quarterly expectations with $1.14 EPS and $339.38 million in revenue, leading management to raise its fiscal 2027 revenue-growth outlook to 5%-8%. Haemonetics' stock opened at $87.50, close to its 12-month high, with a consensus price target of $90.89 from analysts.
HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $95 FROM $89
Barrington Research has increased its target price for Haemonetics Corp (HAE.N) to $95 from $89. This adjustment reflects an updated valuation for the company. The article cites Reuters as the source of this information.
Earnings call transcript: Haemonetics beats Q1 2026 estimates, stock slips premarket
Haemonetics (HAE) reported stronger-than-expected fiscal first-quarter results, with adjusted EPS of $1.14 on revenue of $339 million, exceeding analyst estimates. Despite the beat and raised full-year revenue guidance, the stock declined 1.91% in premarket trading, indicating investor focus on the company's cautious outlook and margin pressures. The company highlighted broad-based growth across its MedSurg, Interventional Technologies, and Apheresis platforms, driven by product launches, market share gains, and the successful rollout of Persona PLUS.
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Haemonetics Corp (HAE), detailing its current price momentum score of 4.19 and its trading range between a resistance level of $91.33 and a support level of $75.97. It evaluates various technical indicators, including MACD, RSI, and moving averages, offering buy, sell, or neutral signals, and concludes with a neutral signal based on today's moving averages and other technical indicators.
HAEMONETICS CORP 2026: Revenue $339.38M, EPS $0.72— 10-Q Summary
HAEMONETICS CORP reported strong financial results for the 2026 quarter, with revenue increasing by 5.6% year-over-year to $339.38 million. Diluted EPS also saw a rise to $0.72. The company attributed its revenue growth to expanded Apheresis plasma volume and market share gains in its MedSurg business, alongside benefits from a higher-margin product mix.
HAEMONETICS CORP : BTIG RAISES TARGET PRICE TO $96 FROM $84
BTIG has raised its target price for Haemonetics Corp (HAE.N) to $96 from $84. This news, reported by Reuters, indicates an updated valuation for the medical technology company.
Haemonetics (NYSE: HAE) grows revenue 5.6% in Q1 2027
Haemonetics Corporation (NYSE: HAE) reported a 5.6% increase in net revenues for Q1 fiscal 2027, reaching $339.38 million. Operating income grew by 6.7% to $57.46 million, while diluted EPS rose 2.9% to $0.72. The company also detailed its segment reorganization into Apheresis and MedSurg, and its financial position including debt repayment and share repurchase programs.
BTIG raises Haemonetics stock price target to $96 on strong results
BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating after the company reported strong first-quarter revenues and adjusted earnings per share that surpassed consensus estimates. All segments performed well, with Interventional Technologies returning to growth and Plasma revenue benefiting from market share gains. Despite a recent stock decline due to cautious outlook and margin pressures, Haemonetics raised its fiscal 2027 revenue guidance, and InvestingPro analysis suggests the stock remains undervalued.
BTIG raises Haemonetics stock price target to $96 on strong results
BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating, following the company's strong first-quarter revenue of $339.4 million and adjusted EPS of $1.14, both exceeding consensus estimates. All segments surpassed expectations, and the company raised its fiscal 2027 revenue growth guidance. Despite strong results, the stock recently declined due to investor concerns about a cautious outlook and margin pressures.
Haemonetics sets Aug. 6 webcast to discuss fiscal Q1 results
Haemonetics (NYSE: HAE) announced that its financial results for the first quarter of fiscal 2027, which ended June 27, 2026, are now available on its Investor Relations website. The company will host an investor conference call and live webcast on August 6, 2026, at 8:00 a.m. ET to discuss these results, with a replay available for one year. Following the announcement, HAE's stock saw a moderate positive market reaction, gaining 3.30%.
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Haemonetics Corporation announced that its first quarter fiscal year 2027 financial results, for the period ending June 27, 2026, are now available on its Investor Relations website. The company will also host a conference call and webcast on August 6, 2026, at 8:00 a.m. ET to discuss these results. Supplemental earnings materials are also posted online for reference during the call.
Haemonetics Reports Q1 FY2027: Revenue $339.4M, Adjusted EPS $1.14, Raises FY27 Guidance
Haemonetics announced its first-quarter fiscal 2027 results, reporting net revenue of $339.4 million, a 5.6% year-over-year increase, and adjusted earnings per diluted share of $1.14. The company raised its full-year fiscal 2027 revenue and organic growth targets, attributing the strong performance to plasma share gains and momentum in Blood Management Technologies. Haemonetics also reiterated its guidance for adjusted operating margin expansion and free cash flow conversion.
Haemonetics earnings up next as estimates cool ahead of print
Haemonetics Corporation is set to report its first-quarter fiscal 2027 results, with analysts expecting a sequential decline in earnings and revenue. Investors will be focused on explanations for the anticipated revenue drop, margin sustainability, and updates on growth catalysts like recent FDA approvals. Despite the cooling estimates, Wall Street maintains a favorable view of the company.
Haemonetics (HAE) Is Up 5.1% After New VASCADE MVP XL Real-World Study Data Release – Has The Bull Case Changed?
Haemonetics (HAE) saw its stock rise by 5.1% following the release of new real-world study data for its VASCADE MVP XL venous vascular closure system. The study from Emory University indicated rapid hemostasis, high same-day discharge rates, and low complication rates for the device. This positive clinical validation could strengthen Haemonetics' investment narrative, though competitive pressures and U.S. market concentration remain key risks.
Can New VASCADE MVP XL Data Strengthen Haemonetics' (HAE) Moat in Electrophysiology Adjacent Markets?
Haemonetics (HAE) recently published data from a large Emory University study showing its VASCADE MVP XL venous vascular closure system achieved rapid hemostasis and low complication rates in electrophysiology procedures. This real-world evidence, following an FDA label expansion, strengthens the clinical case for VASCADE MVP XL and supports Haemonetics' investment narrative by reinforcing its position in key medical markets. Despite this positive development, the article notes that investors still need to consider risks related to market competition and dependence on a few key products.
Haemonetics study shows VASCADE MVP XL posts 1.2% vascular complications in 1,623 large-bore electrophysiology cases
A new retrospective study on Haemonetics' VASCADE MVP XL device, published by Public Technologies (PUBT) and sourced from PR Newswire, demonstrates a low 1.2% vascular complication rate in 1,623 large-bore electrophysiology procedures. The study highlights the device's efficacy in fast vessel closure, support for same-day discharge, and a favorable safety profile without the need for surgical interventions. These findings reinforce the expanded US labeling for the device, cleared in March 2026.
Haemonetics stock hits 52-week high at 87.49 USD
Haemonetics (HAE) stock reached a 52-week high of $87.49, reflecting an 81% increase from its 52-week low and a 14.4% total return over the past year. Analysts have a positive outlook, with Mizuho raising its price target to $85 and BofA Securities upgrading the stock to Buy, citing strong performance and conservative guidance. The company recently surpassed Q4 fiscal year 2026 earnings and revenue expectations and restructured its financial reporting segments for better alignment.
Haemonetics (HAE) Appoints Martin Madaus To Its Board With Diagnostics Experience
Haemonetics Corporation (NYSE:HAE) has appointed Dr. Martin Madaus to its Board of Directors, bringing significant diagnostics and life sciences experience. This appointment is part of an ongoing Board refresh and governance effort, signaling a potential sharpened focus in product portfolios, partnerships, and capital allocation for the medical technology company. Investors will be watching how Dr. Madaus's background influences future priorities, particularly given the company's current P/E ratio and debt levels.
Haemonetics study shows safety data for vascular closure device
Haemonetics Corporation announced the publication of a study demonstrating the safety and effectiveness of its VASCADE MVP XL venous vascular closure system. The study, funded by Haemonetics and conducted at Emory University, involved 1,623 patients undergoing large-bore venous access electrophysiology procedures, showing a low complication rate and high same-day discharge rate. This data supports the FDA's expanded labeling approval for the device in March 2026.
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
A new study published by Haemonetics Corporation provides further evidence of the safety and efficacy of its VASCADE MVP® XL venous vascular closure system. The retrospective cohort study, conducted at Emory University, involved 1,623 patients undergoing electrophysiology procedures with large bore sheaths, demonstrating rapid hemostasis, a high same-day discharge rate, and a strong safety profile. This reinforces the system's value for PFA, LAAC, and concomitant procedures, especially following its expanded FDA labeling in March 2026.
